Literature review on antiobesity medication use for metabolic and bariatric surgery patients from the American Society for Metabolic and Bariatric Surgery Clinical Issues Committee


      The following literature search is in response to inquiries made to the American Society for Metabolic and Bariatric Surgery (ASMBS) regarding antiobesity medication (AOM) use in patients who are having or have already had metabolic and bariatric surgery (MBS). These recommendations are based on current clinical knowledge, expert opinion, and published peer-reviewed scientific evidence available at this time. This paper is not intended to establish a local, regional, or national standard of care. The paper will be revised in the future as additional evidence becomes available.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery for Obesity and Related Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Garvey W.
        • Mechanick J.
        • Brett E.
        • et al.
        American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.
        Endocrine Practice. 2016; 22: 1-203
        • Grossman D.
        • Bibbins-Domingo K.
        • Curry S.
        • et al.
        Screening for obesity in children and adolescents: U.S. Preventive Services Task Force recommendation statement.
        JAMA. 2017; 317: 2417-2426
        • Styne D.
        • Arslanian S.
        • Connor E.
        • et al.
        Pediatric obesity—assessment, treatment, and prevention: an Endocrine Society clinical practice guideline.
        J Clin Endocrinol Metab. 2017; 102: 709-757
        • Apovian C.
        • Aronne L.
        • Bessesen D.
        • et al.
        Pharmacological management of obesity: an Endocrine Society clinical practice guideline.
        J Clin Endocrinol Metab. 2015; 100: 342-362
        • Jensen M.
        • Ryan D.
        • Donato K.
        • et al.
        Executive summary: Guidelines (2013) for the management of overweight and obesity in adults.
        Obesity (Silver Spring). 2014; 22: S5-39
        • Heymsfield S.
        • Greenberg A.
        • Fujioka K.
        • et al.
        Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial.
        JAMA. 1999; 282: 1568-1575
        • Broberger C.
        Hypothalamic cocaine- and amphetamine-regulated transcript (CART) neurons: histochemical relationship to thyrotropin-releasing hormone, melanin-concentrating hormone, orexin/hypocretin and neuropeptide Y.
        Brain Res. 1999; 848: 101-113
        • Elias C.
        • Lee C.
        • Kelly J.
        • et al.
        Leptin activates hypothalamic CART neurons projecting to the spinal cord.
        Neuron. 1998; 21: 1375-1385
        • Xu J.
        • McNearney T.
        • Chen J.
        Impaired postprandial releases/syntheses of ghrelin and PYY3-36 and blunted responses to exogenous ghrelin and PYY3-36 in a rodent model of diet-induced obesity.
        J Gastroenterol Hepatol. 2011; 26: 700-705
        • Gibbs J.
        • Young R.
        • Smith G.
        Cholecystokinin decreases food intake in rats.
        Obes Res. 1997; 5: 284-290
        • Cota D.
        • Proulx K.
        • Smith K.
        • et al.
        Hypothalamic mTOR signaling regulates food intake.
        Science. 2006; 312: 927-930
        • Stuber G.
        • Evans S.
        • Higgins M.
        • Pu Y.
        • Figlewicz D.
        Food restriction modulates amphetamine-conditioned place preference and nucleus accumbens dopamine release in the rat.
        Synapse. 2002; 46: 83-90
        • Cummings D.
        • Baskin D.
        • Schwartz M.
        • Morton G.
        • Barsh G.
        Central nervous system control of food intake and body weight.
        Nature. 2006; 443: 289-295
        • Srivastava G.
        • Apovian C.M.
        Current pharmacotherapy for obesity.
        Nat Rev Endocrinol. 2018; 14: 12-24
        • Kumar R.B.
        • Srivastava G.
        • Reid T.J.
        • Aronne L.J.
        Understanding the pathophysiologic pathways that underlie obesity and options for treatment.
        Expert Rev Endocrinol Metab. 2021; 16: 321-338
        • Ochner Kwok Y.
        • Conceicao E.
        • Pantazatos S.P.
        • et al.
        Selective reduction in neural responses to high calorie foods following gastric bypass surgery.
        Ann Surg. 2011; 253: 502-507
        • Van de Sande-Lee S.
        • Pereira F.R.S.
        • Cintra D.E.
        • et al.
        Partial reversibility of hypothalamic dysfunction and changes in brain activity after body mass reduction in obese subjects.
        Diabetes. 2011; 60: 1699-1704
        • Schultes E.B.
        • Wilms B.
        • Thurnheer M.
        • Hallschmid M.
        Hedonic hunger is increased in severely obese patients and is reduced after gastric bypass surgery.
        Am J Clin Nutr. 2010; 92: 277-283
        • Romanova I.V.
        • Ramos E.J.
        • Xu Y.
        • et al.
        Neurobiologic changes in the hypothalamus associated with weight loss after gastric bypass.
        J Am Coll Surg. 2004; 99: 887-895
        • Nadreau B.E.
        • Samson P.
        • Blouin A.
        • et al.
        Effects of the biliopancreatic diversion on energy balance in the rat.
        Int J Obes. 2006; 30: 419-429
        • Meguid M.M.
        • Glade M.J.
        • Middleton F.A.
        Weight regain after Roux-en-Y: a significant 20% complication related to PYY.
        Nutrition. 2008; 24: 832-842
        • Kushner R.
        Weight loss strategies for treatment of obesity: lifestyle management and pharmacotherapy.
        Prog Cardiovasc Dis. 2018; 61: 246-252
        • Mordes J.
        • Liu C.
        • Xu S.
        Medications for weight loss.
        Curr Opin Endocrinol Diabetes Obes. 2015; 22: 91-97
        • Velazquez A.
        • Apovian C.
        Updates on obesity pharmacotherapy.
        Ann NY Acad Sci. 2018; 1411: 106-119
        • Package Wegovy.
        Novo Nordisk, 2021
        • Yanovski S.
        • Yanovski J.
        Naltrexone extended-release plus bupropion extended-release for treatment of obesity.
        JAMA. 2015; 313: 1213-1214
      1. Optimal Resources for Metabolic and Bariatric Surgery Manual presents updated program standards for overweight and obese patients. States News Service, 2019 Jul 11
        • Sun Y.
        • Liu B.
        • Smith J.K.
        • et al.
        Association of preoperative body weight and weight loss with risk of death after bariatric surgery.
        JAMA Netw Open. 2020; 3: e204803
        • Mocanu V.
        • Marcil G.
        • Dang J.
        • Birch D.
        • Switzer N.
        • Karmali S.
        Preoperative weight loss is linked to improved mortality and leaks following elective bariatric surgery: an analysis of 548,597 patients from 2015–2018.
        Surg Obes Relat Dis. 2021; 17: 1146-1153
        • Kim J.J.
        • Rogers A.M.
        • Ballem N.
        • Schirmer B.
        ASMBS updated position statement on insurance mandated preoperative weight loss requirements.
        Surg Obes Relat Dis. 2016; 12: 955-959
        • Hutcheon D.
        • Hale A.
        • Ewing J.
        • et al.
        Short-term preoperative weight loss and postoperative outcomes in bariatric surgery.
        J Am Coll Surg. 2018; 226: 514-524
        • Alexandrou A.
        • Felekouras E.
        • Giannopoulos A.
        • Tsigris C.
        • Diamantis T.
        What is the actual fate of super-morbid-obese patients who undergo laparoscopic sleeve gastrectomy as the first step of a two-stage weight-reduction operative strategy?.
        Obes Surg. 2012; 22: 1623-1628
        • Malone M.
        • Alger-Mayer S.
        • Lindstrom J.
        Use of orlistat 60 mg in the management of weight loss before bariatric surgery.
        Ann Pharmacother. 2012; 46: 779-784
        • Ard J.
        • Beavers D.
        • Hale E.
        • Miller G.
        • McNatt S.
        • Fernandez A.
        Use of phentermine-topiramate extended release in combination with sleeve gastrectomy in patients with BMI of 50 kg/m2 or more.
        Surg Obes Relat Dis. 2019; 15: 1039-1043
        • Istfan Lipartia M.
        • Anderson W.A.
        • Hess D.T.
        • Apovian C.M.
        Approach to the patient: management of the post–bariatric surgery patient with weight regain.
        J Clin Endocrinol Metab. 2020; 106: 251-263
        • Colquitt J.
        • Pickett K.
        • Loveman E.
        • Frampton G.
        • Colquitt J.
        Surgery for weight loss in adults.
        Cochrane Database Syst Rev. 2014; 2014: CD003641
        • Sudlow A.
        • Le Roux C.
        • Pournaras D.
        Review of advances in anti-obesity pharmacotherapy: implications for a multimodal treatment approach with metabolic surgery.
        Obes Surg. 2019; 29: 4095-4104
        • Nor Hanipah Z.
        • Nasr E.
        • Bucak E.
        • et al.
        Efficacy of adjuvant weight loss medication after bariatric surgery.
        Surg Obes Relat Dis. 2018; 14: 93-98
        • Stanford F.C.
        • Alfaris N.
        • Gomez G.
        • et al.
        The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study.
        Surg Obes Relat Dis. 2016; 13: 491-500
        • Stanford F.
        Controversial issues: A practical guide to the use of weight loss medications after bariatric surgery for weight regain or inadequate weight loss.
        Surg Obes Relat Dis. 2019; 15: 128-132
        • Suliman M.
        • Buckley A.
        • Al Tikriti A.
        • et al.
        Routine clinical use of liraglutide 3 mg for the treatment of obesity: outcomes in non-surgical and bariatric surgery patients.
        Diabetes Obes Metab. 2019; 21: 1498-1501
        • Wharton S.
        • Kuk J.
        • Luszczynski M.
        • Kamran E.
        • Christensen R.
        Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery.
        Clin Obes. 2019; 9: E12323
        • Srivastava G.
        • Buffington C.
        A specialized medical management program to address post-operative weight regain in bariatric patients.
        Obes Surg. 2018; 28: 2241-2246
        • Thakur U.
        • Bhansali A.
        • Gupta R.
        • Rastogi A.
        Liraglutide augments weight loss after laparoscopic sleeve gastrectomy: a randomised, double-blind, placebo-control study.
        Obes Surg. 2021; 31: 84-92
        • Toth A.
        • Gomez G.
        • Shukla A.
        • et al.
        Weight loss medications in young adults after bariatric surgery for weight regain or inadequate weight loss: a multi-center study.
        Children (Basel). 2018; 5: 116
        • Schwartz J.
        • Suzo A.
        • Wehr A.
        • et al.
        Pharmacotherapy in conjunction with a diet and exercise program for the treatment of weight recidivism or weight loss plateau post-bariatric surgery: a review.
        Obes Surg. 2016; 26: 452-458
        • Gazda C.L.
        • Clark J.D.
        • Lingvay I.
        • Almandoz J.P.
        Pharmacotherapies for post-bariatric weight regain: real-world comparative outcomes.
        Obesity (Silver Spring). 2021; 29: 829-836
        • Edgerton C.
        • Mehta M.
        • Mou D.
        • Dey T.
        • Khaodhiar L.
        • Tavakkoli A.
        Patterns of weight loss medication utilization and outcomes following bariatric surgery.
        J Gastrointest Surg. 2021; 25: 369-377
        • Badurdeen D.
        • Hoff A.
        • Hedjoudje A.
        • et al.
        Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss.
        Gastrointest Endosc. 2021; 93 (e1): 1316-1324
        • Mosli M.
        • Elyas M.
        Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?.
        Saudi J Gastroenterol. 2017; 23: 211
        • Badurdeen D.
        • Hoff A.
        • Barrichello S.
        • et al.
        Efficacy of liraglutide to prevent weight regain after retrieval of an adjustable intra-gastric balloon: a case-matched study.
        Obes Surg. 2021; 31: 1204-1213
        • Mehta S.S.
        • Dawod E.
        • Hajifathalian K.
        • et al.
        Impact of adjunctive pharmacotherapy with intragastric balloons for the treatment of obesity.
        Am Surg. 2021; 31348211038579
        • Srivastava G.
        • Fox C.K.
        • Kelly A.S.
        • et al.
        Clinical considerations regarding the use of obesity pharmacotherapy in adolescents with obesity.
        Obesity (Silver Spring). 2019; 27: 190-204
        • Woo T.
        Pharmacotherapy and surgery treatment for the severely obese adolescent.
        J Pediatr Health Care. 2009; 23: 206-212
        • Browne A.F.
        Therapeutic options to treat pediatric obesity.
        Gastrointest Endosc Clin North Am. 2017; 27: 313-326
        • Ryder J.
        • Kaizer A.
        • Jenkins T.
        • Kelly A.
        • Inge T.
        • Shaibi G.
        Heterogeneity in response to treatment of adolescents with severe obesity: the need for precision obesity medicine.
        Obesity (Silver Spring). 2019; 27: 288-294
        • Czepiel K.
        • Perez N.
        • Reyes K.
        • Sabharwal S.
        • Stanford F.
        Pharmacotherapy for the treatment of overweight and obesity in children, adolescents, and young adults in a large health system in the US.
        Front Endocrinol (Lausanne). 2020; 11: 290
        • Mechanick J.
        • Apovian C.
        • Brethauer S.
        • et al.
        Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures–2019. Update cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic and Bariatric Surgery.
        Obesity Medicine Association, and American Society of Anesthesiologists. Obesity (Silver Spring). 2020; 28: O1-58
        • Gadde K.
        • Martin C.
        • Berthoud H.
        • Heymsfield S.
        Obesity pathophysiology and management.
        J Am Coll Cardiol. 2018; 71: 69-84
        • Elhag W.
        • El Ansari W.
        • Abdulrazzaq S.
        • Elsherif M.
        • Mustafa I.
        Lorcaserin vs. phentermine among non-surgical and surgical obese patients: anthropometric, glycemic, lipid, safety and cost outcomes.
        Ann Med Surg. 2019; 45: 75-81